- Home
- VTRS
VTRS
Viatris Inc.
as 07-26-2024 4:00pm EST
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CANONSBURG |
| Market Cap: | 12.9B | IPO Year: | N/A |
| Target Price: | $12.33 | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.74 - $13.62 | Next Earning Date: | 08-08-2024 |
| Revenue: | $15,361,200,000 | Revenue Growth: | -2.78% |
| Revenue Growth (this year): | -0.75% | Revenue Growth (next year): | -1.48% |
Stock Insider Trading Activity of Viatris Inc. (VTRS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Malik Rajiv | VTRS | Director | Jun 13 '24 | Sell | $10.52 | 85,660 | $900,740.60 | 909,819 | SEC Form 4 |
| Malik Rajiv | VTRS | Director | Jun 13 '24 | Sell | $10.18 | 264,300 | $2,690,283.27 | 645,519 | SEC Form 4 |
| Roman Brian | VTRS | Chief Legal Officer | May 28 '24 | Sell | $10.38 | 89,419 | $928,428.54 | 67,723 | SEC Form 4 |
| Mauro Anthony | VTRS | See Remarks | Mar 13 '24 | Sell | $12.09 | 250,000 | $3,023,700.00 | 243,044 | SEC Form 4 |
| Lyons Dillon JoEllen | VTRS | Director | Mar 3 '24 | Sell | $12.36 | 20,000 | $247,200.00 | 58,714 | SEC Form 4 |
| Campbell Paul | VTRS | See Remarks | Mar 2 '24 | Sell | $12.33 | 24,353 | $300,272.49 | 153,826 | SEC Form 4 |
| Ni Xiangyang (Sean) | VTRS | President, Greater China | Mar 2 '24 | Sell | $12.54 | 17,755 | $222,637.05 | 94,581 | SEC Form 4 |
| Ni Xiangyang (Sean) | VTRS | President, Greater China | Mar 2 '24 | Sell | $12.36 | 3,777 | $46,676.92 | 90,804 | SEC Form 4 |
| Cuneo Andrew | VTRS | See Remarks | Feb 23 '24 | Sell | $13.50 | 4,000 | $54,000.00 | 34,795 | SEC Form 4 |
| Cuneo Andrew | VTRS | See Remarks | Feb 15 '24 | Sell | $12.50 | 4,000 | $50,000.00 | 38,795 | SEC Form 4 |
| Cuneo Andrew | VTRS | See Remarks | Jan 4 '24 | Sell | $11.50 | 4,000 | $46,000.00 | 42,795 | SEC Form 4 |
| Cuneo Andrew | VTRS | See Remarks | Dec 14 '23 | Sell | $10.50 | 4,000 | $42,000.00 | 46,795 | SEC Form 4 |
| Ni Xiangyang (Sean) | VTRS | President, Greater China | Nov 23 '23 | Sell | $9.37 | 14,937 | $139,941.77 | 64,658 | SEC Form 4 |
Latest Viatris Inc. News
VTRS Breaking Stock News: Dive into VTRS Ticker-Specific Updates for Smart Investing
Motley Fool
7 hours ago
3 Surprisingly Underrated Stocks to Buy Right Now
ACCESSWIRE
3 days ago
Viatris 2023 Sustainability Report: Building Access Through a Global and Flexible Supply Chain
ACCESSWIRE
8 days ago
Viatris 2023 Sustainability Report: Our Strategy and Model for Sustainable Access to Medicine
Zacks
16 days ago
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Pharmaceutical Technology
22 days ago
Viatris closes $3.37bn divestitures with OTC deal
MT Newswires
23 days ago
Viatris Divests Over-the-Counter Business to Cooper Consumer Health
PR Newswire
23 days ago
Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
MT Newswires
24 days ago
Viatris Says US Department of Justice's Antitrust Division No Longer Considers Mylan Subject of Investigation
Compare VTRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTRS Viatris Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.